Development of a Hepatoprotective Herbal Drug from Turnera diffusa

Table 1

Activity of different fractions obtained from T. diffusa.

	% recovery	Hepatoprotection, AST (UI/L)	Cytotoxic activity, CC50 μg/mL
ME	12.08	95.33 ± 11.1	49.73 ± 5.03
CME	6.04	82.00 ± 6.08	>500
FrVLC	1.98	41.33 ± 6.50	>500
FrMF	0.47	32.33 ± 5.13	>500
Hepatodamianol		20.23 ± 3.67	>500
Silibinin		81.33 ± 6.02
Doxorubicin			3.12 ± 0.23

Recovery was calculated based on the dry plant. Hepatoprotection model in vitro: HepG2 cells; CCl₄ 0.4% as a damage agent, cells + CCl₄: AST 111.33 ± 3.51, cells without CCl₄: AST 0.66 ± 0.57. Cytotoxicity was assessed in Vero cells; n = 3.